Allena Pharmaceuticals, Inc.
(NASDAQ : ALNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Co.
-0.27%63.771.4%$1739.02m
JNJJohnson & Johnson
0.07%141.440.7%$876.14m
PFEPfizer Inc.
-0.55%38.330.9%$729.42m
MRKMerck & Co., Inc.
0.32%89.240.7%$685.29m
ABBVAbbVie, Inc.
-1.07%87.782.3%$607.65m
LLYEli Lilly & Co.
-0.14%121.531.1%$364.17m
NVSNovartis AG
0.25%93.290.2%$151.08m
AZNAstraZeneca Plc
0.92%48.361.2%$138.40m
GSKGlaxoSmithKline Plc
0.13%45.990.2%$137.93m
SNYSanofi
0.57%49.790.2%$114.51m
RETAReata Pharmaceuticals, Inc.
2.84%206.753.5%$108.66m
KRTXKaruna Therapeutics, Inc.
-11.24%65.250.0%$105.65m
NVONovo Nordisk A/S
1.33%57.250.1%$92.18m
ALLKAllakos, Inc.
-2.21%123.190.0%$74.02m
FTSVForty Seven, Inc.
-7.72%35.750.0%$50.91m

Company Profile

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes Reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.